{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093884","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.392229+00:00","generated_at":"2026-05-31T11:05:31.336398+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Equillium Q2 net income $0.5M, revenue $13.9M; Ono itolizumab option decision by Oct 2024","bullets":["Net income $0.5M ($0.01 EPS) vs net loss $3.3M in Q2 2023; revenue $13.9M (all from Ono collaboration), up from $9.1M.","Cash $33.3M, up $1.0M from Q1 2024; expects to fund operations for at least 12 months, adjusting spending if needed.","Ono option to acquire itolizumab rights decision by Oct 2024; if exercised, Equillium receives JPY 5B (~$35M) plus up to $101.4M milestones.","Phase 3 EQUATOR study (aGVHD) IDMC recommends proceed after positive interim review; no safety or futility concerns.","Positive topline data from Phase 1b EQUALISE (lupus nephritis) and Phase 2 EQ101 (alopecia areata); preparing Phase 2b study in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093884","json":"https://secwatch.observer/filing/0000950170-24-093884.json","markdown":"https://secwatch.observer/filing/0000950170-24-093884.md","text":"https://secwatch.observer/filing/0000950170-24-093884.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000095017024093884/0000950170-24-093884-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000095017024093884/eq-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:05:31.336398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}